Abstract:BACKGROUND AND OBJECTIVE:The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary objective was to describe the quality of life (QoL), tumor control status, drug safety, and clinical/genomic features of active long-term survivors enrolled in the EAP. The secondary objective was to determine the clinical characteristics of long-term survivors in the EAP program. METHODS:In this descriptive observational study, data were collected based on epidemiological research methods. The data of patients who were actively participating in the EAP and still undergoing gefitinib treatment were collected in a cross-sectional manner to reflect the current status of each patient. Meanwhile, the data of patients who had been on gefitinib treatment for more than three years and had already been terminated from the EAP or those who were fast progressors were collected retrospectively. RESULTS:A total of 934 patients were screened in the EAP database. Among these patients, 25 were active long-term survivors still enrolled in the EAP and 34 were long-term survivors who had been terminated from the program. These 59 patients were enrolled in 15 different centers in China, and the remaining 875 patients were fast progressors. The median scores for the Functional Assessment of Cancer Therapy-Lung (FACT-L), Trial Outcome Index (TOI), and Lung Cancer Subscale (LCS) of the 25 long-term survivors were 64.5, 37 and 12.5, respectively. The performance status 0-1 accounted for 91.6% of the data observed during the cross-sectional survey. For active long-term survivors, the objective response rate was 37.5%, the disease control rate was 87.5%, and the median duration of response time was almost 68 months. In the long-term survivor group, no serious and new adverse events were reported. Patients who were aged under 65 years (68.5%), affected with adenocarcinoma (81.4%), female (55.9%), or had never smoked (71%) accounted for majority of the long-term survivors. The percentage of females was significantly higher in the long-term survivor group than in the fast progressor group (P=0.02). Three tissue samples were collected from each of the 24 active long-term survivors, and one patient was found to be positive of EGFR mutation. Twenty-two blood samples were also collected, and one patient tested positive for EGFR mutation. The Ki67 protein expression was also tested in three tissue samples, and two of these were found positive for Ki67 protein expression, with a response duration time of over 73 months. CONCLUSIONS:A 250 mg dose of gefitinib offers good QoL and is safe for advanced NSCLC long-term survivors even after more than three years of treatment. According to the evaluation of the current tumor control statuses of patients, gefitinib demonstrates good efficacy in these active long-term survivors.

The long-term effects of sulindac on familial adenomatous polyposis

Long-term Effects of Sulindac on Familial Adenomatous Poliposis

The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients]

Clinical Study of Sulindac in the Treatment of Sporadic Colorectal Adenomas

P1.12-01 A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC after Second/Third-Line Chemotherapy

Clinical effect of esomeprazole on the prevention of gastric mucosal injury caused by long-term administration of low dose aspirine

Prevention of Pulmonary Fibrosis with Salvianolic Acid A by Inducing Fibroblast Cell Cycle Arrest and Promoting Apoptosis

Gastro-protecting Effect of Gefarnate on Chronic Erosive Gastritis with Dyspeptic Symptoms.

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group

Clinical Investigation on the Efficacy of Maintenance Therapy with Gefitinib in Pulmonary Adenocarcinoma

Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation

Effects of Sulindac on Arylamine N-Acetyltransferase Activity in Human Colon Tumour Cells

[Role of Peroxisome Proliferators-Activated Receptor-Gamma in the Chemical Prevention Therapy of Sulindac for Precancerous Lesions of Rats].

Sulindac, 3,3’-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis

Effects of Folic Acid Therapy on the New-Onset Proteinuria in Chinese Hypertensive Patients: A Post Hoc Analysis of the Renal Substudy of CSPPT (china Stroke Primary Prevention Trial).

Efficacy of Oral Prednisone Acetate for Prevention of Esophageal Stenosis after Endoscopic Submucosal Dissection

Effect of anti-inflammatory molecules from food on organoids derived from adenomatous polyps of FAP subjects

Effects of Long-Term Intraperitoneal Flurbiprofen Axetil on Gastric Mucosa and Liver Function in Rats with Bone Cancer Pain

[Chronic Hepatic Damage in Acute Promyelocytic Leukemia Patients Treated with Tetra-Arsenic Tetra-Sulfide].

Safety and effects of different type of intra-peritoneal implantation of sustained-releasing 5-fluorouracil in patients with gastrointestinal cancer